Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (25355)	2/7/2000 10:29:00 AM
From: Eric Fader	Respond to of 150070

For those who missed MOOR, here's another wireless play. I don't remember if it was ever mentioned on this thread. PFNT, with interesting new wireless technology, is still asking a buck but the chart looks strong. If it breaks through 1-1/16 it's gone. Also PRAV looks like it's playing for keeps this time. Big article ran on Dow Jones on Friday afternoon, with lots of unbelievable forward-looking stuff from the CEO. He compares PRAV to Qualcomm <LOL>, but it's still pretty exciting.

To: SSP who wrote (25355)	2/7/2000 10:29:00 AM
From: SSP	Respond to of 150070

APPI - Advanced Plant Pharmaceuticals Inc. - Announces International Representative Agreement with Santex NEW YORK, Feb. 7 /PRNewswire/ -- Advanced Plant Pharmaceuticals, Inc. (OTC Bulletin Board: APPI) a company that utilizes whole plants to develop all natural dietary supplements, announced that they have signed an International Representative Agreement with Santex, a French corporation, that develops mutually profitable partnerships, and cooperation between distributors and companies engaged in pharmaceutical research, development, manufacture, marketing and distribution. Santex was founded in France in 1979 by senior executives with extensive experience in the international pharmaceutical industry, their purpose being to set up an on-going search for new opportunities on a worldwide basis. The rationale behind the Santex team is to identify, evaluate, and present pharmaceutical opportunities to its international clientele. To meet the demand, the head office located in Riom France has added to its, French team a dedicated network of professionals in Japan, all acting as extended staff to its clients. Santex has agreed to become an international agent focusing on developing overseas distribution outlets for all APPI products. APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has developed ACA, which has potential as an immunomodulator in the treatment of patients infected with the HIV virus as well as increasing energy levels in people that suffer from CFS (chronic fatigue syndrome). APPI has also developed Lo-Chol, a patented cholesterol reducing dietary supplement that in clinical studies along with a proper diet reduced total cholesterol up to 58%. APPI's "Whole Plant" Pharmaceutical Grade Process is a trade secret. Utilization of the APPI process converts single or multiple whole plants into all-natural standardized dietary supplements. The FDA has not approved APPI's products, ACA and Lo-Chol, as nutraceuticals. APPI management feels that the agreement with Santex will lead to relationships with world-class companies who have well-established reputations and distribution capabilities. For more information on APPI, please visit the Company's Web site at advancedplantpharm.com FORWARD-LOOKING STATEMENTS: Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters, herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company. Contact: Barry Clare of Advanced Plant Pharmaceuticals, Inc., 212-695-3334 SOURCE Advanced Plant Pharmaceuticals, Inc. -0- 02/07/2000 /CONTACT: Barry Clare of Advanced Plant Pharmaceuticals, Inc., 212-695-3334/ /Web site: advancedplantpharm.com